On 12 May 2026, authorities across 15 European countries — coordinated by Europol and Eurojust — executed simultaneous actions against a criminal network responsible for the production and distribution of counterfeit medicines and dietary supplements. The operation involved 138 searches, at least 9 arrests, and the seizure of cash, electronic devices, real estate, and other assets worth at least €17.7 million.¹

The network had been operating for nearly two decades and generated an estimated €240 million in illicit transactions, including approximately €70 million in 2021 alone.² Its products were marketed to individuals seeking treatment for serious conditions including diabetes, cancer, and psoriasis, promoted through manipulated advertising and fabricated medical endorsements.

Operations of this scale and duration highlight the structural challenges facing pharmaceutical brand protection in 2026 — and underscore the limits of authentication strategies designed for a less sophisticated counterfeit economy.

Key Facts of the Operation

The verified details from Europol and Eurojust statements:

• Coordinated action across six countries. Searches took place simultaneously in Bulgaria, Greece, Hungary, Poland, Romania, and the Republic of Moldova, with judicial requests extending into ten additional countries.¹
• Industrial-scale production. The central warehouse raided in Bulgaria contained high-tech production machinery, professional packaging lines, tens of thousands of packages spanning more than 300 distinct supplement types, finished products, and ready-to-ship orders.¹
• Professional commercial infrastructure. The network operated through structured companies, call centers in Moldova and Romania, leased warehouses, and hundreds of websites. Romanian authorities blocked 196 sites linked to the scheme; Polish authorities froze €1.8 million in assets.¹
• Marketing built on deception. Investigators identified the use of fabricated medical endorsements and the unauthorized use of public figures' likenesses to convince consumers that the products treated specific diseases.²
• Joint Investigation Team at Eurojust. Established with authorities from Bulgaria, Hungary, Moldova, Poland, and Romania, the JIT coordinated more than ten meetings at Eurojust's headquarters in The Hague before the action day.²

The operation demonstrates how organized criminal groups can replicate legitimate pharmaceutical supply chain processes at industrial scale.

Implications for Patient Safety and Industry Trust

The public-health dimension is direct. Patients seeking treatment for serious conditions risk substituting unauthorized products for prescribed therapies, with consequences ranging from delayed treatment to direct harm. Europol described the network as exploiting the vulnerability of individuals seeking treatments for serious diseases — a characterization that captures both the criminal model and the systemic risk to public health systems.¹

The duration of the operation is itself analytically significant. A network active for nearly two decades operated through the introduction of the EU Falsified Medicines Directive, the rollout of unique-identifier serialization across the European Medicines Verification System, and the maturation of online pharmacy enforcement. This underscores a structural reality: even comprehensive regulatory frameworks operate with significant lag against well-funded criminal infrastructure that reinvests profits over decades.

ForgeStop has previously analyzed this pattern across multiple verticals. In Counterfeiting Is Worse Than You Think, anonymized signals from ForgeStop's AI intelligence platform suggest networks of comparable sophistication operate continuously across pharma, spirits, and cosmetics — not in isolation, but in parallel.

For legitimate manufacturers, the impact compounds: erosion of brand trust, diversion of regulatory and security resources, and the reputational risk of having authorized products convincingly impersonated to vulnerable patients.

Limitations of Traditional Anti-Counterfeiting Measures

The Bulgaria seizure inventory makes a specific point empirically: industrial counterfeiters can replicate holograms, watermarks, serialized 2D codes, and full packaging artwork convincingly enough to pass at retail. Finished counterfeit products were produced to be visually indistinguishable from originals on a pharmacy shelf.

Print-based or visual security features alone are increasingly insufficient against well-resourced, long-operating criminal networks. The reasons are structural:

• Visual security features can be photographed, scanned, and reproduced at industrial scale once the artwork is known.
• Serialized 2D codes — including GS1 DataMatrix — can be harvested from legitimate packaging and reprinted onto counterfeit goods in volume.
• Tamper-evident packaging features designed for visual inspection provide no verification path for the patient at the point of use.

As explored in QR Code vs NFC for Brand Protection, print-based authentication — including QR codes and serialized matrices — can be photographed and reprinted at scale. Cryptographic NFC shifts the verification surface from artwork to silicon, where reproduction becomes a fundamentally different problem.

The Role of Cryptographic NFC Authentication

A growing share of pharmaceutical brand protection programs are moving toward digital-physical authentication that combines cryptographic security with tamper-evident hardware. ForgeStop's NFC platform was designed for the threat profile exposed by operations of this scale.

The platform's core capabilities:

• Cryptographic NFC tags with unit-level unique keys. Every tag is individually keyed and server-verified on each scan, eliminating mass reproduction from a single compromised credential.
• AES-encrypted chip authentication. Cloning a tag requires cloning the underlying silicon — a barrier orders of magnitude higher than reproducing print artwork.
• Tamper-evident hardware. Physical seals are integrated with the chip; once broken, the tag's state changes irreversibly and is detectable on any subsequent scan.
• Real-time scan intelligence. Every interaction generates supply chain data, surfacing geographic anomalies, duplicate scans, and re-circulation patterns within hours rather than years.

Unit-level cryptographic authentication shifts brand protection from periodic enforcement to continuous verification — every package in circulation becomes both a sensor for the brand and a verification surface for the patient. Product Authentication and Anti-Counterfeiting for the Pharmaceutical Industry outlines the full architecture.

Solutions of this kind address the specific vulnerabilities exposed in industrial-scale counterfeiting operations.

Regulatory Context

The May 2026 operation is one visible instance of a broader structural enforcement effort. The EU Falsified Medicines Directive remains the regulatory baseline this network operated through, and the European Medicines Agency's electronic Product Information (ePI) rollout — proceeding through 2026 — is establishing a digital infrastructure layer that will eventually allow real-time verification of authorized product information at the point of dispensation.

Europol's broader Operation SHIELD VI, which ran from April through November 2025, reported 3,354 prosecutions, 907 investigations launched, and 43 organized crime groups investigated against pharmaceutical-crime targets.³ The May 2026 takedown sits within that operational picture, not outside it.

Brand owners can complement this enforcement architecture; they cannot replace it.

Conclusion

Effective brand protection in pharmaceuticals increasingly requires layered, technology-driven strategies that evolve with the threat. The Europol operation demonstrates both the scale of organized pharmaceutical counterfeiting and the limits of authentication strategies that rely solely on visual or print-based security features.

By moving verification from artwork to silicon, the industry can meaningfully strengthen supply chain integrity — and improve protection for the patients these networks deliberately target.

Sources

1. Europol. Europol supports international hit against counterfeit medicines and supplements network. 18 May 2026. Read on europol.europa.eu
2. Eurojust. Takedown of criminal group selling fake medicines and supplements to mislead seriously ill victims. 14 May 2026. Read on eurojust.europa.eu
3. Europol. Operation SHIELD VI summary. February 2026.